# Clinical Impacts of Achieving SVR in Patients With Advanced Hepatic Fibrosis Related to Chronic HCV Treated With Direct Acting Antivirals

> **NCT03884062** · — · COMPLETED · sponsor: **Egyptian Liver Hospital** · enrollment: 3000 (actual)

## Conditions studied

- HCC in Chronic HCV Patients With Advanced Liver Fibrosis

## Interventions

- **DRUG:** DAAs

## Key facts

- **NCT ID:** NCT03884062
- **Lead sponsor:** Egyptian Liver Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-01
- **Primary completion:** 2018-06-01
- **Final completion:** 2019-01-01
- **Target enrollment:** 3000 (ACTUAL)
- **Last updated:** 2020-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03884062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03884062, "Clinical Impacts of Achieving SVR in Patients With Advanced Hepatic Fibrosis Related to Chronic HCV Treated With Direct Acting Antivirals". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03884062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*